Supha Pharmachem Board of Directors

Get the latest insights into the leadership at Supha Pharmachem. Learn about the experienced professionals guiding the company's strategy and governance.

NamePosition
Mr. Mansoor Abdul Vahab Chairman
Mr. Adarsh Munjal Whole Time Director
Mr. Dipesh Vinod Vaidya Independent Director
Ms. Shamim Adil Michal Independent Director
Mr. Vijay Pal Singh Gulya Independent Director
Mr. Bikram Kumar Mund Independent Director

Supha Pharmachem Share price

REMLIFE

0.89

0.00 (0.00%)
Last updated on 16 Dec, 2025 | 15:02 IST
alert_iconwatchlist_icon
BUYSELL
Today's High

0.92

Today's Low

0.88

52 Week Low

0.80

52 Week High

4.27

alert_iconThe current prices are delayed, login to your account for live prices

Supha Pharmachem FAQs

The board at Supha Pharmachem consists of experienced professionals, including Mr. Mansoor Abdul Vahab , Mr. Adarsh Munjal , and others, overseeing the company’s strategic and corporate governance.

Directors at Supha Pharmachem are typically nominated by the Nomination and Remuneration Committee and approved by shareholders, adhering to regulatory and governance standards. While this is the standard procedure, the exact process may differ depending on the company’s internal policies and governance framework.

As of the latest update, Mr. Mansoor Abdul Vahab is the current chairman at Supha Pharmachem.

Executive directors at Supha Pharmachem are involved in day-to-day operations, while non-executive directors, including independents, provide oversight and strategic input. While this distinction is generally followed, the specific responsibilities of executive and non-executive directors may vary based on the company’s organisational structure and governance practices.

Yes, Supha Pharmachem adheres to all applicable SEBI and Companies Act provisions related to board structure, diversity, and independence.

At Supha Pharmachem, board members usually serve fixed terms as outlined in the company’s charter or governance policy, commonly ranging between three to five years, with the possibility of renewal based on performance, shareholder approval, and regulatory norms.